Russian pharmaceutical market 2010
- Дата выхода отчёта: 17 января 2010 г.
- География исследования: Россия
- Период исследования: 2010 (актуализация по запросу)
- Язык отчёта: Английский
- Способ предоставления: электронный
-
Описание
-
Содержание
In 2010, the state played a leading role on the market: the number of legislative initiatives
was unprecedented. This makes the market more open and ordered.
In 2010, the financial indicators of pharmaceutical market were affected both by the consequence
of the crisis, and by government regulation. In 2010, the pharmaceutical market volume
has amounted to 667 billion rubles(including VAT) in end user prices, which is only 6% higher than
that in 2009.
The Russian pharmaceutical market is import oriented. 78% of drugs in money terms consumed
by the population, are produced abroad. Therefore, the ranking of manufacturers is predominantly
occupied by foreign companies: SANOFI-AVENTIS, NOVARTIS. The second line is occupied
by PHARMSTANDART - the only domestic manufacturer in the TOP-20 of leading players in the Russian
pharmaceutical market.
The major playersin the commodity distribution network on the pharmaceutical market are
the distributors. This is due to the geographic specifics of the country - its large area. According
to the results of 2010, the leaders in the distribution segment are CV Protek and SIA International.
Their joint market share amounts to 37%. Specialized distributors (R-PHARM, Pulse) are growing
rapidly.
Pharmacy segment of the Russian market is represented by the huge number of participants.
The largest networks are “36.6”, “Rigla”, “Implozia” - their total share reaches 7%. In 2010,
the pharmacy networks divided into 2 groups: those who continued business optimization (36.6,
Pharmacor, Doctor Stoletov), and those who made investmentsin expanding the quantitative composition
of the network (Rigla, A5, Melodiya Zdorovya).
In 2010, commercial segment of the Russian market shows low growth rate (+6%). Due to
strict governmental control over vital drug inflation, the market has lost one of its main drivers:
increase in drug prices in the commercial segment was minimal +1%, whereas in 30% of products
(vital drugs) the prices have fallen by 4%. Growth of consumption in kind by + 3% may be considered
a positive factor. In 2010 the sales volume in commercial segment amounted to about 406
billion rubles (13.4 billion dollars). This is only by 6% more than in 2009.
